TEVA241115C16500
- 0.02
- -0.21-91.30%
Teva Pharmaceutical Industries Newsroom
Teva Pharmaceutical Industries (NYSE:TEVA) Shareholders Are Still up 85% Over 3 Years Despite Pulling Back 4.0% in the Past Week
US Manufacturing Index Rises To 43, Highest Since 2020
Plant-Based API Market Poised To Hit $52 Billion By 2034, Driven By Psychedelics And Cannabinoids
Unusual Options Activity: CCK, CMG and Others Attract Market Bets, CCK V/OI Ratio Reaches 179.2
EST Nov 15th Morning Delivery - In the last two hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trends.
Druckenmiller made significant adjustments in the third quarter: opened positions in Bank of America and Broadcom, continued to increase holdings in the top position Natera.
Natera's position significantly increased by 80.61% compared to the previous quarter. Druckenmiller also established new positions in Broadcom, banks, and pharmaceutical stocks, while completely liquidating News Corp and telecom company Liberty Global, and reducing shareholding in microsoft.
Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory
Druckenmiller's Duquesne Closes Some Media Holdings, Loads Into Regional Banks, Among Q3 Trades
Assertio Stock Gains Amid Clash With Activist Investor, Q3 Earnings
UBS Upgrades Teva Pharmaceutical Industries(TEVA.US) to Buy Rating, Maintains Target Price $26
Teva to Present at the Jefferies London Healthcare Conference
Are Investors Undervaluing Teva Pharmaceutical Industries (TEVA) Right Now?
UBS Downgrades Teva Pharmaceutical Industries(TEVA.US) to Hold Rating, Maintains Target Price $26
BofA Securities Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Raises Target Price to $23
Barclays Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Maintains Target Price $25
10-Q: Q3 2024 Earnings Report
SA Asks: How Will the U.S. Election Results Impact Healthcare Stocks?
Teva Pharmaceutical Industries Limited (TEVA) Q3 2024 Earnings Call Transcript Summary
Express News | Teva Pharm CEO Francis Says Expects Generics Prices to Be Pushed Down in 2025
Express News | Teva Pharm CEO Francis Says We Think We Have a "Good Case" in Appeal Against European Commission Fine, Appeal Likely to Take Many Years
Teva Gains After Raising Outlook for Second Time This Year